Shares of Regeneron Pharmaceuticals, Inc. (NASD:REGN) climbed 11.78% to $300.32 per share on Jan 14 following the rosy fourth quarter 2013 outlook provided by the company on its eye drug Eylea. As ...

Regeneron Pharmaceuticals, Inc. REGN announced disappointing top-line data from an ongoing phase II CAPELLA study, evaluating Eylea (aflibercept) in combination with rinucumab (an anti-PDGFR-beta ...

Despite Eylea reaching the market first, Roche has eroded a stake of Bayer’s market share with its bispecific antibody Vabysmo. Similar to Eylea, Vabysmo is approved for a range of retinal ...

On a standalone basis, Eylea sales were $1.19 billion in the United States in the fourth quarter of 2024. Eylead HD’s net product sales were $305 million in the fourth quarter of 2024 in the ...

Eylea generated $5.72 billion in total U.S. sales last year, which represented 44% of Regeneron’s overall revenue of $13.12 billion. Related Unlike Regeneron, Bayer doesn't feel as much of a ...

Regeneron Pharmaceuticals Inc. said an extensive investigation into a rare and frightening side effect seen in clusters of patients getting its best-selling drug Eylea has been tied to syringes ...

The treatment, known as aflibercept 8 mg in generic terms, was approved in the U.S. in August 2023 as Eylea HD. Regeneron ( REGN ) expects to recognize ~$123M in U.S. net product sales for the ...

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.

Eylea will run $1,850 per dose, Bloomberg reports, compared with $2,000 for Lucentis, and $16,000 for a full year, compared with $24,000 for the Roche drug.

The eye-drug pricing war just got tighter for Roche’s injection Lucentis: An NIH-funded study comparing Lucentis (ranibizumab) against its cancer drug Avastin (bevacizumab) as well as Regeneron’s ...

Kodiak Sciences Inc's eye drug failed to match Regeneron Pharmaceuticals' Eylea in improving the vision of patients in a study, sending its shares tumbling nearly 80% on Wednesday.